Nimorazole

Phase 3Small molecule

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Nimorazole is one of 124 small molecule programs targeting Head and Neck Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

123

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head and Neck Squamous Cell CarcinomaActive, not recruiting

HypoxiaActive, not recruiting

Squamous Cell CarcinomaActive, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 3

Active, not recruiting

HypoxiaPhase 3

Active, not recruiting

Squamous Cell CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

281 competitors in Head and Neck Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

36 2

Erbitux

IImclone

Phase 3

26 3

Beyfortus

BeiGene

Phase 3

7 4

Imfinzi

AstraZeneca

Phase 3

5 5

Ibrance

Pfizer

Phase 3

4 6

Taxotere

AAvyxa

Phase 3

16 7

Lenvima

Eisai

Phase 3

4 8

Imjudo

AstraZeneca

Phase 3

1 9

Tuoyi

CCoherus Oncology, Inc.

Phase 3

6 10

Tecentriq

Roche

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

N/AActive, not recruiting

Squamous Cell Carcinoma

NCT04124198

Clinical

Trials by Indication[1]

Hypoxia1 trial

DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.

Unknown status·DDanish Head and Neck Cancer Group·Phase 3·NCT02661152·1,252 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)

Completed·TThe Christie NHS Foundation Trust·Phase 3·NCT01950689·338 enrolled

Squamous Cell Carcinoma1 trial

Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma

Active, not recruiting·CChristian von Buchwald·N/A·NCT04124198·138 enrolled

HNSCC1 trial

AF CRT +/- Nimorazole in HNSCC

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT01880359·640 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Nimorazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nimorazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nimorazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — European Organisation for Research and Treatment of Cancer - EORTC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEuropean Organisation for Research and Treatment of Cancer - EORTC

Nimorazole

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Hypoxia1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Squamous Cell Carcinoma1 trial

HNSCC1 trial

References

Drug Info

Quick Facts

Related News